

News

Curidium Medica plc ("Curidium" or the "Company")

CURIDIUM TO PRESENT AT THE NEURODRUG 2007 CONFERENCE

London, UK, 22 October 2007, Curidium Medica plc, (LSE: CUR) the personalized medicine company focused on bringing the right drug to the right patient, announces that it will be presenting at NeuroDrug 2007, in London, UK which focuses on drug discovery and development across the Central Nervous System ("CNS) sector.

Dr. Anne Bruinvels, Founder & Chief Scientific Officer will be presenting Curidium's recent progress in identifying targeted medicines and companion diagnostics to treat patients more effectively and discuss the increasing importance of personalized medicine and targeting a drug treatment to a specific sub-population.

The presentation, entitled "Preliminary results of a novel diagnostic test as a key biomarker for CNS disorders", is scheduled at 10.15 hours local time on 23rd October 2007 at the Royal Garden Hotel in London.

Dr. Bruinvels will also be participating at the 12 panel session, entitled "What makes the most effective biomarkers and what alternative methods are available?" discussing the most promising biomarkers for diagnosing and treating CNS disorders and identifying those who distinguish placebo responders in clinical trials.

Ends

For further information, please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc

Anne T. Bruinvels, PhD, +44 (0) 20 7554 8790
Founder & Chief Scientific Officer, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.
3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc © 2002-2007. All rights reserved.

Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791